Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical and electronics industries.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" mentioned in their pipeline regarding their obesity (muscle target) program may ...

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.